Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Common Equity: 2020-2025

Historic Common Equity for Maravai Lifesciences Holdings (MRVI) over the last 5 years, with Sep 2025 value amounting to $431.9 million.

  • Maravai Lifesciences Holdings' Common Equity fell 29.52% to $431.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $431.9 million, marking a year-over-year decrease of 29.52%. This contributed to the annual value of $577.2 million for FY2024, which is 26.92% down from last year.
  • According to the latest figures from Q3 2025, Maravai Lifesciences Holdings' Common Equity is $431.9 million, which was down 7.72% from $468.0 million recorded in Q2 2025.
  • In the past 5 years, Maravai Lifesciences Holdings' Common Equity ranged from a high of $905.2 million in Q4 2022 and a low of $209.8 million during Q1 2021.
  • Its 3-year average for Common Equity is $695.5 million, with a median of $772.5 million in 2024.
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' Common Equity surged by 252.42% in 2021, and later slumped by 39.42% in 2025.
  • Maravai Lifesciences Holdings' Common Equity (Quarterly) stood at $545.4 million in 2021, then skyrocketed by 65.99% to $905.2 million in 2022, then dropped by 12.74% to $789.9 million in 2023, then decreased by 26.92% to $577.2 million in 2024, then decreased by 29.52% to $431.9 million in 2025.
  • Its Common Equity was $431.9 million in Q3 2025, compared to $468.0 million in Q2 2025 and $530.3 million in Q1 2025.